Evaluation of Efficacy and Safety of Vismed Gel Multi 0.3% Versus Vismed Multi 0.18% on Treatment of Ocular Dryness

Evaluation of the Efficacy and Safety of Vismed® Gel Multi 0.3% Versus Vismed® Multi 0.18% on the Treatment of Moderate to Severe Ocular Dryness

This study is a multicentric, comparative, randomized, investigator-blinded, parallel group study to demonstrate the non-inferiority of Vismed® Gel Multi 0.3% in comparison with Vismed® Multi 0.18% in terms of cornea and conjunctiva staining (Oxford score) on patients with moderate to severe ocular dryness, after 35 days of treatment.

Study Overview

• Status: Unknown
• Conditions: Dry Eye
• Intervention / Treatment: Device: Vismed gel Multi 0.3% eye drops; Device: Vismed Multi 0.18% eye drops

Detailed Description

Evaluation of the non-inferiority of Vismed® Gel Multi 0.3% in comparison with Vismed® Multi 0.18%, in terms of cornea and conjunctiva staining (Oxford score), on worse eye, between Day 0 and Day 35.

Evaluation of the non-inferiority of Vismed® Gel Multi 0.3% in comparison with Vismed® Multi 0.18%, in terms of cornea and conjunctiva staining (Oxford score), on worse eye, between Day 0 and Day 35.

• Comparison of Day 35 versus Day 0 and Day 84 versus Day 0 for each product and comparison between products for the following parameters:

  • Evolution of cornea and conjunctiva staining (Oxford score) on worse eye.
  • Evolution of DEQ-5 score (5-items Dry Eye Questionnaire).
  • Evolution of Van Bijsterveld score (Lissamine green staining) in worse eye.
  • Evolution of Schirmer test result in worse eye.
  • Evolution of Tear film Break-Up Time (TBUT) in worse eye.
  • Evolution of ocular dryness severity by evaluation of each main symptom by the patient and total score of all symptoms
  • Evaluation of treatment performance by the investigator and the patient.
• Evaluation of the average frequency of use over 84 days for both products.

• Study Type: Interventional
• Enrollment (Anticipated): 80
• Phase: Not Applicable

Contacts and Locations

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Sex: male or female.
• Age: more than 18 years.
• Subject with a moderate to severe dry eye syndrome needing artificial tears in the 3 months preceding the inclusion.
• Subject having used only artificial tears without preservative (NaCl 0.9%, Hydrabak®) during 1 to 2 weeks before inclusion (up to 6 times a day).
• Subject with a score ≥ 6 for the 5-Item Dry Eye Questionnaire (DEQ-5)

• Subject with at least one eye with:

  • Global ocular staining (cornea and conjunctiva) ≥4 and ≤9 on the Oxford scale (0 to 15)

AND one of the following criteria:

• Schirmer test ≥ 3 mm/5 min and ≤ 9 mm/5 min OR

• Sum of 3 measurements of Tear film Break-Up Time (TBUT) ≤ 30s.

  • Subject, having given freely and expressly his/her informed consent.
  • Subject who is able to comply with the study requirements, as defined in the present CIP, at the Investigator's appreciation.
  • In France: subject being affiliated to a health social security system. Female subjects of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end.

Exclusion Criteria:

• Pregnant or nursing woman or planning a pregnancy during the study.
• Subject deprived of freedom by administrative or legal decision.
• Subject in a social or health institution
• Subject who is under guardianship or who is not able to express his/her consent.
• Subject being in an exclusion period for a previous study.
• Subject suspected to be non-compliant according to the Investigator's judgment.
• Subject wearing contact lenses during the study.
• Far best corrected visual acuity < 1/10

• Subject with severe ocular dryness with one of these conditions:

  • Eyelid or blinking malfunction
  • Corneal disorders not related to dry eye syndrome
  • Ocular metaplasia
  • Filamentous keratitis
  • Corneal neovascularization
• Subject with severe meibomian gland dysfunction (MGD)
• History of ocular trauma, infection or inflammation, not related to dry eye syndrome within the last 3 months prior to the inclusion.
• History of ocular allergy or ocular herpes within the last 12 months.
• Subjects who underwent ocular surgery, including laser surgery, in either eye within the last 6 months.
• Any troubles of the ocular surface not related to dry eye syndrome.
• Subject having used artificial tears in the 6 hours preceding the inclusion visit.
• Use of the following ocular treatments: isotretinoïd, cyclosporine, tacrolimus, sirolimus, pimecrolimus, punctual plugs during the month preceding the inclusion.
• Subjects who have received ocular therapy (either eye) with any ophthalmic medication, except tear substitutes, within 2 weeks prior to study start or expected to receive ocular therapy during the study.
• Any not stabilised systemic treatment, which can have an effect on performance or safety criteria, at the investigator appreciation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Investig. device:Vismed Gel Multi 0.3%; Vismed gel Multi 0.3% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days	Device: Vismed gel Multi 0.3% eye drops; Ophthalmic use. Vismed gel Multi 0.3% eye drops. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
Active Comparator: Comparative device: Vismed Multi 0.18%; Vismed Multi 0.18% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days	Device: Vismed Multi 0.18% eye drops; Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Demonstrate the non-inferiority of Vismed® Gel Multi 0.3% in comparison with Vismed® Multi 0.18% in terms of cornea and conjunctiva staining (Oxford score) on patients with moderate to severe ocular dryness, after 35 days of treatment.	Assess the ocular surface fluorescein staining score- mean change from Baseline in the study at D35 in ocular surface fluorescein stainig score according to a scale from zero to 15	35 days
To assess the total ocular surface fluorescein staining score at D84	Mean change from Baseline (D0) in the study eye and D84 in the total ocular surface fluoresceine staining score	0 and 84 days
Evolution of DEQ-5 score	Evolution from Baseline of DEQ-5 questionnaire scores at day 35	35 days
Evolution of DEQ-5 score	Evolution from Baseline of DEQ-5 questionnaire scores at day 84	84 days
Evolution of Van Bijterveld score ( lissamine green staining)	Mean change from Baseline ( D0) and D 35 in the total Van Bijterveld score	35 Days
Evolution of Van Bijterveld score ( lissamine green staining)	Mean change from Baseline ( D0) and D 84 in the total Van Bijterveld score	84 days
Volume tear fluid secretion as assessed by schirmer test	Mean change from Baseline ( D0) in Volume tear fluid secretion as assessed	35 days
Volume tear fluid secretion as assessed by schirmer test	Mean change from Baseline ( D0) in Volume tear fluid secretion as assessed	84 days
Evolution of Tear film Break-Up Time	Mean change from Baseline (D0) in the study eye in TFBUT at Day 35	35 days
Evolution of Tear film Break-Up Time	Mean change from Baseline (D0) in the study eye in TFBUT at Day 84	84 days
Global sum score of dry eye symptoms at visit 3 - mean change from Baseline at visit 3 ( D35)	Mean change from Baseline in the global sum score of dry eye symptoms at D35 : discomfort,burning, stinging,eye dryness sensation, itching,foreign body sensation,photophobia, blurred vision.Each graded from 0 to 10	35 days
Global sum score of dry eye symptoms at visit 4 - mean change from Baseline at visit 3 ( D84)	Mean change from Baseline in the global sum score of dry eye symptoms at D84 : discomfort,burning, stinging,eye dryness sensation, itching,foreign body sensation,photophobia, blurred vision.Each graded from 0 to 10	84 days
Global treatment performance score assessed by the investigator at visit 3	Total Treatment performance score graded from 0 to 4	35 days
Global treatment performance score assessed by the investigator at visit 4	Total Treatment performance score graded from 0 to 4	84 days
Global treatment performance score assessed by the patient at visit 3	Total Treatment performance score graded from 0 to 4	35 days
Global treatment performance score assessed by the patient at visit 4	Total Treatment performance score graded from 0 to 4	84 days

Collaborators and Investigators

• Sponsor: Horus Pharma
• Investigators: Principal Investigator: Béatrice Cochener-Lamard, Prof, Hôpital Morvan, Brest, France

Study record dates

Study Major Dates

• Study Start (Anticipated): September 1, 2018
• Primary Completion (Anticipated): March 1, 2019
• Study Completion (Anticipated): June 15, 2019

Study Registration Dates

• First Submitted: August 22, 2018
• First Submitted That Met QC Criteria: August 22, 2018
• First Posted (Actual): August 24, 2018

Study Record Updates

• Last Update Posted (Actual): August 24, 2018
• Last Update Submitted That Met QC Criteria: August 22, 2018
• Last Verified: August 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Lacrimal Apparatus Diseases; Dry Eye Syndromes; Pharmaceutical Solutions; Ophthalmic Solutions
• Other Study ID Numbers: 17E4554; 2018-A01711-54 (Other Identifier: ANSM)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided
• IPD Plan Description: Depending on any journal publication of the results

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No